The Challenge with BCIs: Inflammation, scarring, and programmed cell death undermine performance over time Implantable electrodes within the brain have enabled remarkable achievements—e.g., paralyzed ...
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ ...
An announcement from Hemostemix ( (TSE:HEM)) is now available. Hemostemix has raised C$480,000 through a non-brokered private placement of 4,000,000 common shares priced at C$0.12 each, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results